Characteristics of IPF patients initiating nintedanib, pirfenidone or no antifibrotic treatment in the US

First published 06/06/2019

Last updated 16/10/2026

EU PAS number:

EUPAS30039

Study

Finalised

Download as PDF

Documents

Study protocol

Initial protocol

IQVIA BI IPF channeling AP_12182018_v2

English (683.77 KB - PDF) View document

Study results

1199.375_Synopsis.pdf

English (376.84 KB - PDF) View document

Study report

No information provided.

Other information

Study, other information

study_1199-0375_ct.gov_form

English (404.53 KB - PDF) View document

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

No information provided.

Characteristics of IPF patients initiating nintedanib, pirfenidone or no antifibrotic treatment in the US

Secondary tabs

Share this page